Frank E Bowen

Title: Frank E Bowen: Innovator in Ribavirin Dosage Forms

Introduction

Frank E Bowen is a notable inventor based in Rutherford, NJ (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of orally administrable solid dosage forms of ribavirin. With a total of 5 patents to his name, Bowen's work has the potential to impact the treatment of various medical conditions.

Latest Patents

Bowen's latest patents include innovative formulations that enhance the delivery of ribavirin. One of his key patents describes an orally administrable solid ribavirin dosage form that features a compacted ribavirin composition. This formulation boasts a high tap density of at least 0.6 g/mL, along with rapid disintegration and dissolution rates. Importantly, the ribavirin in this dosage form is substantially free of polymorphic forms, which can affect the drug's efficacy. Another patent further elaborates on the orally administrable solid dosage form, emphasizing its advantageous properties and the process for making such formulations.

Career Highlights

Frank E Bowen is associated with Schering Corporation, where he has been instrumental in advancing pharmaceutical innovations. His work has not only contributed to the company's portfolio but has also played a crucial role in improving patient outcomes through better drug formulations.

Collaborations

Bowen has collaborated with notable colleagues such as Stephen M Liebowitz and Elliot I Stupak. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in the pharmaceutical field.

Conclusion

Frank E Bowen's contributions to the development of ribavirin dosage forms highlight his commitment to advancing pharmaceutical science. His innovative patents and collaborations reflect a dedication to improving healthcare solutions.